Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Completes $16M Private Financing

NEW YORK, April 2 - Orchid Biosciences of Princeton, NJ, today announced the completion of a $16 million private financing.

 

With the blessing of Nasdaq, which last week allowed the company to retain its listing until June 24, and previously granted an exemption for conducting this private financing without shareholder approval, Orchid sold a new issue of convertible preferred stock to a group of institutional investors.

 

The company said that the investors in the private fund-raise included BayStar Capital of LarkSpur, Calif., and SDS Capital Partners of Old Greenwich, Conn.

 

Orchid received a delisting warning notice from Nasdaq on Jan. 3 after trading below $1.00, the minimum bid price required for continued listing on the exchange, for several months. The company appealed and a hearing before a Nasdaq listing qualifications panel was held in February.

 

Orchid sold 1,600 shares of newly issued convertible preferred stock, each convertible into approximately 22,222 shares of common stock. Each preferred share will have a purchase price of $10,000 and include a warrant to purchase approximately 6,667 shares of Orchid's common stock. The shares would be convertible into common stock at a conversion price of $0.45, and the warrants would be exercisable at $0.45 per share, according to the company.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.